Table 1 Baseline demographics and disease history of patients
From: Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
THOMAS-1 | THOMAS-2 | |||
|---|---|---|---|---|
Autoinjector (n = 74) | PFS (n = 75) | Autoinjector (n = 82) | AMD (n = 82) | |
Mean (SD) age, years | 60.6 (9.6) | 61.2 (11.1) | 59.2 (10.0) | 60.1 (10.5) |
Age group | ||||
<65 years | 46 (62) | 42 (56) | 57 (70) | 49 (60) |
≥65 years | 28 (38) | 33 (44) | 25 (30) | 33 (40) |
Female sex | 26 (35) | 36 (48) | 39 (48) | 39 (48) |
Race | ||||
White | 58 (78) | 62 (83) | 75 (92) | 69 (84) |
Black or African American | 7 (10) | 11 (15) | 2 (2) | 6 (7) |
Asian | 7 (10) | 2 (3) | 3 (4) | 4 (5) |
Other | 1 (1) | 0 | 2 (2) | 3 (4) |
Missing | 1 (1) | 0 | 0 | 0 |
Hispanic ethnicity | 6 (8) | 9 (12) | 6 (7) | 4 (5) |
Baseline ezetimibe use | 8 (11) | 1 (1) | 6 (7) | 8 (10) |
NCEP high risk | 38 (51) | 31 (41) | 29 (35) | 37 (45) |
NCEP moderate/moderately high risk | 25 (34) | 29 (39) | 36 (44) | 33 (40) |
Coronary artery disease | 20 (27) | 13 (17) | 13 (16) | 12 (15) |
Type 2 diabetes mellitus | 18 (24) | 17 (23) | 18 (22) | 17 (21) |
Hypertension | 54 (73) | 49 (65) | 49 (60) | 56 (68) |
Cerebrovascular or peripheral artery disease | 6 (8) | 8 (11) | 6 (7) | 14 (17) |
Mean (SD) baseline LDL-C, mg/dLa | 118.1 (28.7) | 116.9 (25.0) | 117.3 (23.9) | 115.3 (27.0) |
Mean (SD) HDL-C, mg/dL | 50.6 (13.3) | 52.1 (14.7) | 49.7 (14.6) | 50.9 (14.5) |
Mean (SD) triglycerides, mg/dL | 143.5 (66.2) | 138.1 (60.4) | 139.9 (48.4) | 147.5 (64.8) |
Mean (SD) non-HDL-C, mg/dL | 146.8 (33.2) | 144.6 (30.2) | 145.3 (26.3) | 144.8 (30.9) |